Bioreactor design for clinical‐grade expansion of stem cells
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The many clinical trials currently in progress will likely lead to the widespread use of stem cell‐based therapies for an extensive variety of diseases, either in autologous or allogeneic settings. With the current pace of progress, in a few years' time, the field of stem cell‐based therapy should be able to respond to the market demand for safe, robust and clinically efficient stem cell‐based therapeutics. Due to the limited number of stem cells that can be obtained from a single donor, one of the major challenges on the roadmap for regulatory approval of such medicinal products is the expansion of stem cells using Good Manufacturing Practices (GMP)‐compliant culture systems. In fact, manufacturing costs, which include production and quality control procedures, may be the main hurdle for developing cost‐effective stem cell therapies. Bioreactors provide a viable alternative to the traditional static culture systems in that bioreactors provide the required scalability, incorporate monitoring and control tools, and possess the operational flexibility to be adapted to the differing requirements imposed by various clinical applications. Bioreactor systems face a number of issues when incorporated into stem cell expansion protocols, both during development at the research level and when bioreactors are used in on‐going clinical trials. This review provides an overview of the issues that must be confronted during the development of GMP‐compliant bioreactors systems used to support the various clinical applications employing stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adult mesenchymal stem cells for tissue engineering versus regenerative medicine
Caplan, A. I. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21200 · Cited by 1,956 · cited 1×
“On the other hand, the clinical impact of MSC is just being presently unveiled through a series of clinical trials for purposes as distinct as tissue engineering or cellular therapy for immunological disorders [40].”
BackgroundScalable Stirred-Suspension Bioreactor Culture of Human Pluripotent Stem Cells
Kehoe, D. E., Jing, D., Lock, L. T., & Tzanakakis, E. S. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0454 · Cited by 264
Bardy, J., Chen, A. K., Lim, Y. M., Wu, S., Wei, S., Weiping, H., Chan, K., Reuveny, S., & Oh, S. K. W. (2013) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2012.0146 · Cited by 111 · cited 1×
“1 × 106 cells/ml [28] integrated iPS cell expansion and differentiation in neural progenitor cells (NPC) (up to 85% efficiency on NPC generation)”
BackgroundFluri, D. A., Tonge, P. D., Song, H., Baptista, R. P., Shakiba, N., Shukla, S., Clarke, G., Nagy, A., & Zandstra, P. W. (2012) · Nature Methods · doi:10.1038/nmeth.1939 · Cited by 106 · cited 1×
“The feasibility of derivation, expansion and differentiation of iPSC in stirred bioreactor systems has been previously demonstrated [37, 38].”
Method
Cited by
Sart, S., Tsai, A.-C., Li, Y., & Ma, T. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0537 · Cited by 382
The Evolution of Polystyrene as a Cell Culture Material
Lerman, M. J., Lembong, J., Muramoto, S., Gillen, G., & Fisher, J. P. (2018) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2018.0056 · Cited by 258
Progress and challenges in large-scale expansion of human pluripotent stem cells
Kropp, C., Massai, D., & Zweigerdt, R. (2017) · Process Biochemistry · doi:10.1016/j.procbio.2016.09.032 · Cited by 167
“For hPSC expansion the implementation of online measureent and the control of process parameters such as DO, pH, vital iomass, and nutrient/metabolites, which has only recently been ntroduced to hPSC cultivation, will be fundamental [22].”
Large‐Scale Production of LGR5‐Positive Bipotential Human Liver Stem Cells
Schneeberger, K., Sánchez‐Romero, N., Ye, S., van Steenbeek, F. G., Oosterhoff, L. A., Pla Palacin, I., Chen, C., van Wolferen, M. E., van Tienderen, G., Lieshout, R., et al. (2020) · Hepatology · doi:10.1002/hep.31037 · Cited by 141
“(14) To enable mass production of viable cell cultures, bioreactors, including spinner flasks, have been used extensively for the large-scale expansion and controlled differentiation of stem cells.(15,16) Bioreactors offer certain advantages including minimization of gradient formation (e.”
BackgroundPigeot, S., Bourgine, P. E., Claude, J., Scotti, C., Papadimitropoulos, A., Todorov, A., Epple, C., Peretti, G. M., & Martin, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197233 · Cited by 15
Metadata
- Authors
- dos Santos, F. F., Andrade, P. Z., da Silva, C. L., & Cabral, J. M. S.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2013-04-26
- Volume
- 8
- Issue
- 6
- Pages
- 644-654
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2158733788
- Cited by
- 105
- References
- 4
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.